Semi-Annual Report — FY2026 H1
What K Pharma,Inc. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-13View the original on EDINET
How much it says
54Typical
What moved here
12named for the first time
Its own wording
30terms
Which filing this is
8/ 8newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period, the company continued to record an operating loss and an interim net loss while incurring research and development expenses, and cash and cash equivalents decreased. The filing also describes, as material agreements, a basic agreement concerning outsourced manufacturing for the KP8011 company-sponsored clinical trial and extensions of the joint research agreements with the Kitasato Institute and Osaka National Hospital.
Komori's summary of this document, not the document's own words.54Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
49
Typical
50
Typical
53
Typical
55
Typical
62
Detailed
53
Typical
11
Almost nothing
50
Typical
R&D spend2億円Money spent making new things.
Cash left over-6億円Cash from the business, less what went into equipment.
Spent on equipment24百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.